• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人卵巢癌的异种生长。一种新的体内测试系统。

Heterologous growth of human ovarian cancer. A new in vivo testing system.

作者信息

Davy M, Mossige J, Johannessen J V

出版信息

Acta Obstet Gynecol Scand. 1977;56(1):55-9. doi: 10.3109/00016347709158340.

DOI:10.3109/00016347709158340
PMID:402784
Abstract

Successful heterotransplantation of ovarian cancer in the mouse mutant, nude is described, with serial transmission, in one case to date. Light and electron microscopic examination of this tumour, a poorly differentiated adenocarcinoma, has not revealed any alteration in its morphology after six passages. Tumour-bearing mice have been treated with ThioTEPA or 5-Fluoro-Uracil, in an attempt to see if they show a similar effect to that seen in the patient. ThioTEPA resulted in a marked regression, whilst there was no effect from 5-Fluoro-Uracil, on tumour growth--confirming the ThioTEPA effect seen in the patient.

摘要

本文描述了在裸鼠这一突变小鼠中成功进行的卵巢癌异种移植,并实现了连续传代,目前已有一例。对该肿瘤(一种低分化腺癌)进行光镜和电镜检查发现,经过六代传代后其形态未发生任何改变。对荷瘤小鼠使用了塞替派或5-氟尿嘧啶进行治疗,试图观察它们是否会产生与患者身上所见类似的效果。塞替派导致肿瘤显著消退,而5-氟尿嘧啶对肿瘤生长没有影响,这证实了在患者身上观察到的塞替派效果。

相似文献

1
Heterologous growth of human ovarian cancer. A new in vivo testing system.人卵巢癌的异种生长。一种新的体内测试系统。
Acta Obstet Gynecol Scand. 1977;56(1):55-9. doi: 10.3109/00016347709158340.
2
[Preoperative chemotherapy of malignant ovarian neoplasms].[恶性卵巢肿瘤的术前化疗]
Vopr Onkol. 1973;19(2):20-3.
3
[Palliative treatment of ovarian cancers with the association of thiotepa and of 5-fluoro-uracil].硫替派与5-氟尿嘧啶联合用于卵巢癌的姑息治疗
Bord Med. 1971 May;4(5):1523-30.
4
High dose thiotepa in ovarian cancer.高剂量噻替派治疗卵巢癌
Indian J Cancer. 1985 Mar;22(1):33-7.
5
Acute myeloblastic leukemia after cure of ovarian cancer.卵巢癌治愈后发生的急性髓细胞白血病。
JAMA. 1974 Oct 21;230(3):418-20.
6
Propagation of a poorly differentiated human pulmonary adenocarcinoma in nude athymic rats.低分化人肺腺癌在无胸腺裸鼠体内的传代
Int J Cancer. 1983 Dec 15;32(6):793-9. doi: 10.1002/ijc.2910320621.
7
Chemotherapy of ovarian cancer with melphalan.用美法仑治疗卵巢癌
Clin Obstet Gynecol. 1968 Jun;11(2):354-66.
8
Establishment of a new ovarian tumor line in nude mice and its application to treatment of the donor patient.裸鼠体内新卵巢肿瘤细胞系的建立及其在供体患者治疗中的应用。
Gynecol Oncol. 1985 Jul;21(3):320-30. doi: 10.1016/0090-8258(85)90270-7.
9
Chemotherapy in the treatment of cancer of the ovary.化疗在卵巢癌治疗中的应用。
Am J Obstet Gynecol. 1970 Jul 1;107(5):691-703. doi: 10.1016/s0002-9378(16)33987-4.
10
[Effect of Thio-TEPA on advanced ovarian cancer (author's transl)].硫替派对晚期卵巢癌的作用(作者译)
Tumori. 1973 Jul-Aug;59(4):259-67. doi: 10.1177/030089167305900402.

引用本文的文献

1
Harnessing preclinical models for the interrogation of ovarian cancer.利用临床前模型探究卵巢癌。
J Exp Clin Cancer Res. 2022 Sep 16;41(1):277. doi: 10.1186/s13046-022-02486-z.
2
Current Status of Patient-Derived Ovarian Cancer Models.患者来源的卵巢癌模型的现状。
Cells. 2019 May 25;8(5):505. doi: 10.3390/cells8050505.
3
Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma.高级别浆液性卵巢癌患者来源异种移植瘤的组织学和分子分析
J Hematol Oncol. 2016 Sep 21;9(1):92. doi: 10.1186/s13045-016-0318-6.
4
Establishment and characterization of intraperitoneal xenograft models by co-injection of human tumor cells and extracellular matrix gel.通过共注射人肿瘤细胞和细胞外基质凝胶建立并表征腹腔内异种移植模型。
Oncol Lett. 2015 Dec;10(6):3450-3456. doi: 10.3892/ol.2015.3764. Epub 2015 Sep 29.
5
Establishment of a new representative model of human ovarian cancer in mice.建立一种新的人卵巢癌小鼠代表性模型。
J Ovarian Res. 2013 Feb 6;6(1):9. doi: 10.1186/1757-2215-6-9.
6
Human carcinoma cell lines xenografted in athymic mice: biological and antigenic characteristics of an intraabdominal model.移植于无胸腺小鼠体内的人癌细胞系:一种腹腔内模型的生物学和抗原特性
Cancer Immunol Immunother. 1987;24(1):13-8. doi: 10.1007/BF00199827.